Presentation is loading. Please wait.

Presentation is loading. Please wait.

Drug levels during the course of a dosing interval.

Published byFerdinand Shepherd Modified over 5 years ago

Similar presentations

Presentation on theme: "Drug levels during the course of a dosing interval."— Presentation transcript:

1 Drug levels during the course of a dosing interval.
Drug levels during the course of a dosing interval. The drug concentration is lowest (Cmin) just before the dose is taken, then rises to a peak level (Cmax) at a certain time after the dose (Tmax). The concentration then falls back to Cmin before the next dose. The area under the concentration-time curve (AUC) describes total drug exposure during the entire dosing interval. Jeffrey Schiff et al. CJASN 2007;2: ©2007 by American Society of Nephrology

Download ppt "Drug levels during the course of a dosing interval."

Similar presentations

Applications of Pharmacokinetics

Applications of Pharmacokinetics
From: A Simulation Study of Common Propofol and Propofol-Opioid Dosing Regimens for Upper Endoscopy:Implications on the Time Course of Recovery Anesthes.

From: A Simulation Study of Common Propofol and Propofol-Opioid Dosing Regimens for Upper Endoscopy:Implications on the Time Course of Recovery Anesthes.
Suggested approach to patients with dabigatran-associated bleeding

Suggested approach to patients with dabigatran-associated bleeding
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.

Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.
Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,

Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,
Figure Diagrammatic levodopa pharmacokinetics after single doses of immediate release (IR) carbidopa/levodopa (CD/LD) and 3 strengths of extended release.

Figure Diagrammatic levodopa pharmacokinetics after single doses of immediate release (IR) carbidopa/levodopa (CD/LD) and 3 strengths of extended release.
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Within-group comparisons of adjusted mean±SEM of absolute change in peak systolic strain (%) from baseline to 12 months using the American Heart Association.

Within-group comparisons of adjusted mean±SEM of absolute change in peak systolic strain (%) from baseline to 12 months using the American Heart Association.
Table e-1 Geometric Mean Ratio 90% Confidence Limit of AUC(0-t)

Table e-1 Geometric Mean Ratio 90% Confidence Limit of AUC(0-t)
ROC curves. ROC curves. The four plots represent the ROC curves from the following four prediction models for day 3 AKI: RAI (A), NGAL and RAI (B), MMP-8.

ROC curves. ROC curves. The four plots represent the ROC curves from the following four prediction models for day 3 AKI: RAI (A), NGAL and RAI (B), MMP-8.
Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.

Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.
Receiver operating characteristic curves of prediction models.

Receiver operating characteristic curves of prediction models.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)

Adjusted means (±SD) of eGFR in relation to the histologic severity of nonalcoholic steatohepatitis (i.e., NASH/fibrosis stage increasing from 0 to 3)

Similar presentations

Ads by Google